FGEN—(-20%/AH)—fails again in DMD: https://www.globenewswire.com/news-release/2023/08/29/2733891/33525/en/FibroGen-Announces-Topline-Results-from-LELANTOS-2-a-Phase-3-Clinical-Study-of-Pamrevlumab-in-Ambulatory-Duchenne-Muscular-Dystrophy.html